In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRISTOL-MYERS SQUIBB ACQUIRES LIPHA GLUCOPHAGE MARKETING RIGHTS

Executive Summary

BRISTOL-MYERS SQUIBB ACQUIRES LIPHA GLUCOPHAGE MARKETING RIGHTS in the U.S. for the pending product for treatment of non- insulin dependent diabetes mellitus (NIDDM) or Type II diabetes, the company announced April 27. Financial terms of the agreement, which is effective immediately, were not disclosed. In exchange, Lipha gains marketing rights in France to BMS's once-a-day ACE inhibitor fosinopril (Monopril) for the treatment of hypertension and congestive heart failure. The Lyon, France-based company will receive marketing rights to additional unnamed BMS products in Europe at a later date, BMS said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel